Clinical trial
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
NCT04802876 is registered in ClinicalTrials.gov with SOLTI Breast Cancer Research Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
- Lead sponsor
- SOLTI Breast Cancer Research Group
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- April 12, 2021
- Completion date
- March 31, 2027
- Enrollment
- 184 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
anal carcinoma, carcinoma of unknown primary, cervical carcinoma, cholangiocarcinoma, colorectal adenocarcinoma, epithelial ovarian cancer, esophageal adenocarcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, her2-positive breast cancer, hormone receptor positive / her2-negative breast cancer, kidney clear cell carcinoma, lung adenocarcinoma, lung adenocarcinoma egfr-mutated/ alk traslocation, lung squamous cell carcinoma, melanoma, mesothelioma, msi-h colorectal cancer, other histology, pancreatic adenocarcinoma, prostate adenocarcinoma, sarcoma, small cell lung cancer, squamous esophageal carcinoma, stomach adenocarcinoma, thyroid carcinoma, triple negative breast cancer, urothelial carcinoma, uterine adenocarcinoma, uterine carcinosarcoma, uveal melanoma